Therefore, BEL's MOA against lung cancer may involve a direct inhibition of STAT3/COX-2 signaling cascades, thereby affecting the caspase-dependent apoptosis pathway and, ultimately, cancer cell damage (Figure 19). The gene discussed is PTGS2; the disease is lung cancer.